Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 05, 2026 | June 09, 2026 |
| Flexion Therapeutics IncFLXN · Entity 16545 | Director | June 10, 2020 | June 12, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, CFO & CBO | May 11, 2020 | July 10, 2020 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 07, 2022 | June 10, 2022 |
| Vor Biopharma Inc.VOR · Entity 4763 | CFO | December 05, 2025 | December 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05 | Direct | 13,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Flexion Therapeutics Inc
Report date June 10, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,500 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Grant · Acquired 4,500 · Balance 4,500 F1: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 7,000 |
Reported balance
After 2020-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-10 · Grant · Acquired 7,000 · Balance 7,000 F2: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant.
Sarepta Therapeutics, Inc.
Report date May 11, 2020 · Filed July 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,260 |
Ending reported balance
After 2020-07-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-05-11 · Gift · Disposed 20,425 · Balance 16,454 F1: This transaction involved a gift of shares of common stock by the reporting person to family trusts. Row 2 · 2020-07-08 · Exercise / conversion · Acquired 2,385 · Balance 18,839 Row 3 · 2020-07-08 · Exercise / conversion · Acquired 218 · Balance 19,057 Row 4 · 2020-07-08 · Exercise / conversion · Acquired 1,203 · Balance 20,260 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-08 · Exercise / conversion · Disposed 2,385 · Balance 0 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-08 · Exercise / conversion · Disposed 218 · Balance 0 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.63 · Expires 2027-03-10 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-08 · Exercise / conversion · Disposed 1,203 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 12,012 |
Reported balance
Holding disclosure · report date 2020-05-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 12,012 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involved a gift of shares of common stock by the reporting person to family trusts.
Spyre Therapeutics, Inc.
Report date June 07, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2032-06-06 | Direct | 43,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 43,000 · Balance 43,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Vor Biopharma Inc.
Report date December 05, 2025 · Filed December 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 694,137 · Balance 0 F1: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split. F2: On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.80 · Expires 2035-12-04 | Direct | 1,388,274 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Grant · Acquired 1,388,274 · Balance 1,388,274 F3: The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above. F4: 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split.
F2: On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025.
F3: The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above.
F4: 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2019 Filed Mar 30, 2019 00:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021878 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,378 F1 · price: The transaction reflects the vesting of previously granted performance-based restricted stock units. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 43 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · derivative · entry 10 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478 Underlying: Common Stock · 43 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 164 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · derivative · entry 9 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Underlying: Common Stock · 164 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 3,511 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · derivative · entry 8 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 Underlying: Common Stock · 3,511 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 11,768 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · derivative · entry 7 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,768 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,625 | $126.47 | $331,983.75 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · nonDerivative · entry 5 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,729 F1 · kind: Represents shares of common stock owned by the reporting person that were delivered to the Company to pay the aggregate exercise price with respect to the option exercises reported on this Form 4 filing. Such an "option swap" enables the exercise and holding of shares of Common Stock by the reporting person. F1 · shares: Represents shares of common stock owned by the reporting person that were delivered to the Company to pay the aggregate exercise price with respect to the option exercises reported on this Form 4 filing. Such an "option swap" enables the exercise and holding of shares of Common Stock by the reporting person. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 43 | $13.71 | $589.53 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · nonDerivative · entry 4 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 164 | $13.71 | $2,248.44 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · nonDerivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 3,511 | $13.90 | $48,802.90 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 11,768 | $23.85 | $280,666.80 |
DisclosureSEC source: 0001209191-19-020686 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:08 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 55,000 | $0.00 Strike: $145.48 | $0.00 |
DisclosureSEC source: 0001209191-19-016041 · doc4.xml · derivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2029-03-04 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 01:08 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Disposition to issuerCommon Stock | 4,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016041 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,868 F1 · shares: Forfeiture of 4,781 shares of restricted stock due to performance goal not met. Read SEC document |
| February 07, 2019 Filed Feb 9, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-19-008776 · doc4.xml · derivative · entry 4 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,466 Underlying: Common Stock · 65,000 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on October 29, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 07, 2019 Filed Feb 9, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 65,000 | $145.00 | $9,425,000.00 |
DisclosureSEC source: 0001209191-19-008776 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,649 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on October 29, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 07, 2019 Filed Feb 9, 2019 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 65,000 | $23.85 | $1,550,250.00 |
DisclosureSEC source: 0001209191-19-008776 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on October 29, 2018. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 31, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 21,198 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · derivative · entry 13 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,466 Underlying: Common Stock · 21,198 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 31, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 21,198 | $130.72 | $2,771,002.56 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · nonDerivative · entry 7 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,649 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 31, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 21,198 | $23.85 | $505,572.30 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · nonDerivative · entry 6 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 19,345 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · derivative · entry 12 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,664 Underlying: Common Stock · 19,345 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 17,860 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · derivative · entry 11 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,860 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 1,128 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · derivative · entry 10 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,771 Underlying: Common Stock · 1,128 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 5,469 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · derivative · entry 9 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,404 Underlying: Common Stock · 5,469 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 43,802 | $130.00 | $5,694,260.00 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · nonDerivative · entry 5 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,649 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 19,345 | $23.85 | $461,378.25 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · nonDerivative · entry 4 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 17,860 | $13.90 | $248,254.00 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · nonDerivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,128 | $13.71 | $15,464.88 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 01:24 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,469 | $13.71 | $74,979.99 |
DisclosureSEC source: 0001209191-19-006627 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 11,718 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · derivative · entry 11 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,873 Underlying: Common Stock · 11,718 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F7 · derivative.exercise_date: The option vests based on time criteria (25% of the total option on 2/29/2017 and 1/48th of the total option in equal monthly installments thereafter). Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 29,080 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · derivative · entry 10 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,899 Underlying: Common Stock · 29,080 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: Half of the total options granted began vesting when the FDA provided marketing approval for eteplirsen on 9/19/2016 and the other half of the total options granted began vesting when Sarepta Therapeutics, Inc. filed a Marketing Authorization Application with the European Medicines Agency on 11/30/2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vested immediately upon achievement of the performance condition (25% of the total performance-based options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total performance-based options granted) vest over four years. 25% of the remaining options vested on the first year anniversary of the grant date, or 2/28/2017 and 1/48th of the remaining options vests monthly thereafter. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 39,006 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · derivative · entry 9 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,860 Underlying: Common Stock · 39,006 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The option vests based on time criteria (25% of the total option on 2/27/2016 and 1/48th of the total option in equal monthly installments thereafter). Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 9,596 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · derivative · entry 8 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,009 Underlying: Common Stock · 9,596 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The option to purchase shares is fully vested. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GiftCommon Stock | 12,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · nonDerivative · entry 7 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 12,012 F3 · kind: This transaction involved a gift of securities by the reporting person to his wife. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GiftCommon Stock | 12,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · nonDerivative · entry 6 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,649 F3 · kind: This transaction involved a gift of securities by the reporting person to his wife. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 107,524 | $127.74 | $13,735,115.76 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · nonDerivative · entry 5 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,661 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: The shares were sold in multiple transactions at prices ranging from $120.87 to $134.39, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 11,718 | $13.71 | $160,653.78 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · nonDerivative · entry 4 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 29,080 | $13.71 | $398,686.80 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · nonDerivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 39,006 | $13.90 | $542,183.40 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 22:43 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 9,596 | $23.85 | $228,864.60 |
DisclosureSEC source: 0001209191-18-056332 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 08, 2018 Filed Aug 8, 2018 22:14 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 8,501 | $121.02 | $1,028,791.02 |
DisclosureSEC source: 0001209191-18-045903 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,785 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of performance-based restricted stock award granted on September 19, 2016. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 16:16 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $28.14 | $0.00 |
DisclosureSEC source: 0001209191-18-038938 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 22:45 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 18,400 | $0.00 Strike: $10.28 | $0.00 |
DisclosureSEC source: 0001140361-18-027929 · doc1.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2028-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033111 · doc4.xml · derivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,649 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units. F3 · derivative.expiration_date: On March 10, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units, and the second performance criterion was met on May 22, 2018, resulting in vesting of 25% of such restricted stock units. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,024 | $89.22 | $180,581.28 |
DisclosureSEC source: 0001209191-18-033111 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,286 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 10, 2017. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 6,649 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-033111 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:08 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 2,500 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-18-020347 · doc4.xml · derivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,768 Underlying: Common Stock · 2,500 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:08 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 734 | $81.22 | $59,615.48 |
DisclosureSEC source: 0001209191-18-020347 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,661 F1 · shares: The Reporting Person delivered already-owned shares of Common Stock in payment of the option exercise price. Such an "option swap" enables the exercise and holding of shares of Common Stock by the Reporting Person. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:08 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,500 | $23.85 | $59,625.00 |
DisclosureSEC source: 0001209191-18-020347 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 97,500 | $0.00 Strike: $71.45 | $0.00 |
DisclosureSEC source: 0001209191-18-017792 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,500 Underlying: Common Stock · 97,500 shares Expires 2028-03-05 F1 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| December 01, 2017 Filed Dec 6, 2017 02:03 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001140361-17-045125 · doc1.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-11-30 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:42 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionRestricted Stock Units · Derivative | 13,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047901 · doc4.xml · derivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,298 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. F3 · derivative.expiration_date: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.